Publications by authors named "J Sibilia"
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?
Ther Adv Musculoskelet Dis
October 2024
Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disease causing chronic inflammation in joints and other organs, leading to potential joint damage and increased health risks if not properly managed.
- Interleukin-6 (IL-6) is a key cytokine involved in RA, making it a significant target for treatment; therapies like tocilizumab can block IL-6 receptors and help reduce inflammation.
- Personalizing RA treatment based on individual patient profiles and addressing related health issues can improve outcomes, with a focus on a 'treat-to-profile' strategy that considers the patient's overall health.
Introduction: The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren's disease (SjD) can be suspected from the results of two phase II clinical trials but has not been evaluated in an animal model of the disease. We aimed to evaluate the therapeutic efficacy of this strategy on dryness and salivary gland (SG) infiltrates in the NOD mouse model of SjD.
Material And Methods: Female NOD mice between ages 10 and 18 weeks were treated with a BAFF-blocking monoclonal antibody, Sandy-2 or an isotype control.
Because Systemic Lupus Erythematosus (SLE) is a rare disease, and due to the significant prognostic impact of early management, a diagnosis confirmed by a physician with experience in SLE is recommended, for example from an expert center. Once the diagnosis is confirmed, existing manifestations should be identified in particular, renal involvement by an assessment of proteinuria, disease activity and severity should be determined, potential complications anticipated, associated diseases searched for, and the patient's socioprofessional and family context noted. Therapeutic management of SLE includes patient education on recognizing symptoms, understanding disease progression as well as when they should seek medical advice.
View Article and Find Full Text PDFBackground: Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
Aims: To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
Methods: We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023.